View More
Review the latest evidence on HER2 testing, clinical implications of HER2-low status in advanced breast cancer, and mastering the safety profile of antibody-drug conjugates, including current guidelines and expert’s recommendations.
Download this short summary slideset of key takeaways from a live satellite symposium on new developments in precision care for advanced HER2-low breast cancer.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.